Company profile
Mucosis company profile
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Business identity
- Website
- http://www.mucosis.com
- Contact email
- [email protected]
- Phone number
- +31508200050
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2006-01-01, Year
Headquarters
- Headquarters
- Ten Boer, Groningen, The Netherlands
- Postal code
- 9713 GX
- Country code
- NL
- Continent
- Europe